Table 2.

Univariate analysis for DFS

Variable		HR	95% CI for HR	p
Age (year)	Median	0.991	0.960–1.022	0.556
Menopausal status	Pre vs. Post	1.205	0.588–2.468	0.610
Surgical status	BCS vs. MRM	0.417	0.178–0.973	0.043
Hormone-Receptor Status	Negative vs. Positive	1.246	0.374–4.141	0.720
HER2-Status	Negative vs. Positive	2.669	1.049–6.785	0.039
TNBC	Yes vs. No	1.944	0.952–13.939	0.131
Histology	ILC vs. IDC	1.103	0.260–4.678	0.894
Stage	III vs. II	4.408	1.685–11.532	0.002
Grade	III vs. I+II	2.106	0.954–4.647	0.065
Perineural invasion	Negative vs. Positive	0.535	0.217–1.312	0.172
Lymphovascular invasion	Negative vs. Positive	0.854	0.418–1.741	0.664
pT-Stage	3+4 Vs 1+2	3.166	1.514–6.617	0.002
pN-Stage	1			<0.001
	2	2.246	0.686–7.346	0.181
	3	11.134	3.723–33.292	<0.001
Lymph Node Removed		1.000	0.955–1.047	0.997
Metastatic Lymph Node		1.089	1.029–1.152	0.003
LNR	<0.21			<0.001
	0.21–0.65	6.180	1.377–27.734	0.017
	>0.65	23.628	5.430–102.806	<0.001
Surgical Margin	Negative vs. Positive	0.656	0.088–4.867	0.680
Adjuvant Treatment	Doxorubicin			0.916
	Doxorubicin +taxane	0.948	0.437–2.055	0.893
	taxane	0.647	0.083–5.026	0.677
Adjuvant Trastuzumab	Yes vs No	0.364	0.143–0.922	0.033
Adjuvant Hormonotherapy	Yes vs No	0.726	0.274–1.920	0.518
Adjuvant Hormonotherapy	Aromatase inhibitors vs Tamoxifen	0.528	0.239–1.165	0.114
Adjuvant Radiotherapy	No vs Yes	1.350	0.318–5.717	0.683

BCS: Breast-conserving Surgery; HER2: Human Epidermal Growth Factor Receptor 2; ILC: Invasive Lobular Carcinoma; IDC: Invasive Ductal Carcinoma; LNR: Lymph Node Ratio; MRM: Modified Radical Mastectomy; pT: Pathologic Tumor Stage; pN: Pathologic Lymph Node Stage; SD: Standard Deviation; TNBC: Triple-Negative Breast Cancer; DFS: Disease-free Survival